Riding high, Johnson & Johnson reported pharmaceutical sales worth $13.89 billion on Tuesday (Oct 17), a year-over-year growth exceeding 5%. The pharmaceuticals driving its growth are Darzalex, a biologic used for multiple myeloma, and Erleada, a prostate cancer treatment, in addition to several other oncology...
Healthcare giant Johnson & Johnson (J&J) said Tuesday (Oct. 18) that strong pharmaceutical sales and a recovery in medical procedures helped offset economic headwinds and currency-related losses from the strong US dollar. In discussing its third quarter earnings, which saw total revenues rise just 1.9%...
